Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
Crohn's & Colitis 360 · 01.01.2023 · 5 (1)
DOI: 10.1093/crocol/otad001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 12.01.2023. Verfasst von Katsumasa Nagano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceutical K.K., Medical affairs division, Tokyo, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical K.K., Tokyo, Japan.
Abstract (Originalsprache)
Background
To present the real-world evidence on the safety and effectiveness of ustekinumab (UST) through 52-week treatment for Crohn’s disease (CD) under an analysis of post-market surveillance data in Japan.
Methods
This prospective, post-marketing surveillance study was conducted in 341 patients from 91 medical facilities in Japan. Patients received UST 90 mg injected subcutaneously once every 12 weeks (or every 8 weeks if patients show weak effectiveness) after an induction dose given intravenously. Clinical response (100-point decrease in Crohn’s Disease Activity Index [CDAI] score), clinical remission (CDAI score of <150), steroid-free clinical remission, C-reactive protein, endoscopy, physician global assessment, and adverse drug reactions (ADRs) were evaluated through 52 weeks.
Results
The overall rate of clinical remission was 49.2% at week 8 and 56.0% at week 52. The rate of clinical remission in biologic-naive patients was 75.9% and 66.7% at weeks 8 and 52, respectively, whereas the rate in biologic-experienced patients was 41.4% and 52.6% at weeks 8 and 52, respectively. For 52 weeks, the overall incidence of ADRs and serious adverse drug reactions (SADRs) was 11.7% and 6.7%, respectively. The most frequently reported SADRs was worsening of CD (1.8%). In multivariate analysis, ADRs incidence was significantly lower in patients with ileal involvement of CD (odds ratio = 0.25, 95% CI 0.07–0.85, P = .026), although disease location has no association with effectiveness of UST.
Conclusions
The present study identified no new safety concerns and effectiveness for CD in Japanese patients treated with UST.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Janssen Pharmaceutical K.K., Medical affairs division, Tokyo, Japan.
- Janssen Pharmaceutical K.K., Research & Development division, Tokyo, Japan.
- Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.
ORCID-Profile: Katsumasa Nagano
Förderung
- Janssen Pharmaceutical K.K., Tokyo, Japan
Zitieren
APA
Nagano, K., Hata, E., Asano, T., Tsuchiya, H., Takagishi, M., Yamazaki, H., Tominaga, S., & Matsumoto, T. (2023). Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed. Crohn's & Colitis 360, 5(1). https://doi.org/10.1093/crocol/otad001
Vancouver
Nagano K, Hata E, Asano T, Tsuchiya H, Takagishi M, Yamazaki H, et al. Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed. Crohn's & Colitis 360. 2023;5(1). doi:10.1093/crocol/otad001
BibTeX
@article{Nagano2023,
author = {Nagano, Katsumasa and Hata, Erina and Asano, Teita and Tsuchiya, Hiroaki and Takagishi, Masayuki and Yamazaki, Hiroshi and Tominaga, Sonoko and Matsumoto, Takayuki},
title = {Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed},
journal = {Crohn's & Colitis 360},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/crocol/otad001}
}
EUVIMED